Tempus AI, Inc.
TEMQ3 2024(TEM Q2 FY2024)Estimated26.2% AI
AI Revenue %
26.2%
AI Fair Value
$1.0B
AI Revenue (Q)
$43.5M
Total Revenue (Q)
$166.0M
Source: SEC EDGAR 10-Q Filing
View 10-Q on SEC.govAnalysis
Q2 FY2024: Genomics $112.3M, D&S $53.6M, Total $166.0M. AI from Genomics ($112.3M x 10% = $11.2M) + AI from D&S ($53.6M x 60% = $32.2M) = $43.4M / $166.0M = 26.2%. D&S share rose to 32.3%, highest in recent quarters, driven by strong Insights/Trials performance. Company IPO'd in June 2024.
Analyzed by claude-opus-4-6
Quoted Figures
Genomics $112,324, Data and services $53,645, Total net revenue $165,969 for three months ended June 30, 2024.
10-Q for period ending June 30, 2024 (Income Statement)
The Company recognized revenue for clinical orders of $101.7 million for the three months ended June 30, 2024. Genomics revenue for direct bill orders of $10.6 million.
10-Q for period ending June 30, 2024 (Revenue Recognition note)
AI Products Identified (Ring 1)
Lens AI platform (analytics)Intelligent DiagnosticsAlgorithmic clinical trial matchingDe-identified data licensing with AI curation
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
Genomic sequencing (clinical orders $101.7M, direct bill $10.6M)Lab operations and clinical billing
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix